The world’s battle against emerging diseases and endemic threats demands rapid, effective solutions. The recent evolution of viruses like SARS-CoV-2 underscores the need for innovative antibody discovery methods that can keep pace with mutations. Introducing the Bruker Cellular Analysis Beacon® optofluidic system, a revolutionary tool that’s reshaping the fight against diseases.
In our latest Application Note, “Empowering Rapid and Robust Antibody Response: The Role of Next-Generation Antibody Discovery in Preparedness for Emerging Diseases and Endemic Threats,” we delve into how the Beacon system is transforming antibody discovery. From its ability to screen thousands of single B cells in a day to its role in identifying potent antibodies against evolving threats, this technology is shaping a resilient response against diseases.
Key Highlights of the Application Note:
- The Beacon system’s accelerated antibody discovery process.
- Rapid response: How the Beacon system contributed to AstraZeneca’s Evusheld antibody therapy.
- Staying ahead of mutations: Identifying broadly neutralizing antibodies for next-gen therapeutic mAbs and vaccines.
- The role of Beacon in early identification of Omicron-neutralizing antibodies.
Ready to Dive Deeper?
Discover how the Bruker Cellular Analysis Beacon system is redefining the fight against emerging diseases. To access the full Application Note and explore the transformative potential of this technology, download it here. Join us in the pursuit of preparedness and innovation in the face of global health challenges.
